30 TECHNOLOGY: REALISING THE FULL POTENTIAL OF THERAPEUTIC NITRIC OXIDE

30 Technology Enrolls First Patient in Pioneering NOPA Trial for New Inhaled Antimicrobial RESP303

30 Technology is excited to announce that on October 16, 2024, the first patient was enrolled into the NOPA study.

30 Technology announces interim results from Phase 2 tuberculosis trial

30 Technology is pleased to announce the successful completion of the interim analysis for Stage 1 of the Phase 2 trial evaluating RESP301 in the treatment of tuberculosis (RESP30X-EBA).

30 Technology- EMA Approval to launch a Phase 1/2a trial in patients with Non-Cystic Fibrosis Bronchiectasis

30 Technology is thrilled to announce approval for our Phase 1/2a trial designed to evaluate the safety, tolerability, and efficacy of nebulised Nitric Oxide Formulations

30 TECHNOLOGY is developing nitric oxide-generating technologies for a range of health care applications